Developer docs
API playgroundTry for free, no card

Search company profiles

Biomaster

Full company profile

uuid002hmb7

Namestring
Biomaster
Legal namestring
株式会社バイオマスター (Biomaster, Inc.)
Websiteurl
biomaster.jp
Company typeenum
Private
Founded yearint
2002
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersYokohama, Japan
HQ citystring
Yokohama
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative medicine services, cell processing services, adipose stem cell therapy, cell concentration systems, breast reconstruction treatment
Industry3 codes
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAL
GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGAIAG
Cell Culture & Bioprocess Lab Equipment (Bioreactors, Single-Use Systems, Controllers)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Surgical & Medical Instruments & Apparatus3841
Product category
Regenerative Medicine Services
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Cell Processing Contract Business (细胞加工受托事业)
TypeProfessional Services
Description

Medical institutions send collected adipose tissue, Biomaster separates and cultures adipose-derived stem cells at its registered Cell Processing Facility (CPC) and returns them. Revenue is generated through cell processing fees charged to medical institutions. The CPC is registered with the Ministry of Health, Labour and Welfare under the Act on the Safety of Regenerative Medicine.

biomaster.jp
2Cell Concentration Washing System Sales
TypeHardware Sales
Description

Sale of the Kaneka-developed cell concentration washing system and disposable kits to medical institutions. Institutions use the system for in-house SVF separation and extraction.

biomaster.jp
3Clinic Services (Cellport Clinic Yokohama)
TypeProfessional Services
Description

Direct patient services through the company's own clinic, providing CAL and cultured CAL breast reconstruction and related treatments. Operated under the Structural Reform Special Zones Act.

biomaster.jp
4Application and Technical Support Services
TypeProfessional Services
Description

Support services for medical institutions seeking to offer regenerative medicine, including preparation of application documents for the Regenerative Medicine Safety Act, technical guidance, and physician/technician dispatch as needed.

biomaster.jp
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 3 records shown
1CAL組織増大術 (CAL)
Description

Cell Assisted Lipotransfer - regenerative medicine technique combining patient fat with adipose-derived stem cells to improve fat graft survival rates

biomaster.jp
+2 more records
Core offering1 text field

Biomaster is a regenerative medicine research and development company that provides cell processing contract services, cell concentration washing systems, and regulatory/technical support to medical institutions in Japan. It also operates Cellport Clinic Yokohama, where it delivers proprietary CAL (Cell Assisted Lipotransfer), Cultured CAL, and Step-CAL breast reconstruction and regenerative treatments directly to patients using adipose-derived stem cells.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 1,300+ CAL procedures performed (as of June 2021)
+2 more records
Product overview1 text field

Biomaster is a research and development company specializing in regenerative medicine, offering a portfolio of three integrated regenerative medicine solutions: (1) Cell Processing Contract Business for third-party medical institutions, (2) Cell Concentration Washing System (KaneKa) equipment sales, and (3) Application/Technical Support for regenerative medicine approvals. Additionally, Biomaster operates Cellport Clinic Yokohama, which directly provides CAL (Cell Assisted Lipotransfer) and Cultured CAL treatments to patients, including the branded stem cell product PortStem.

Product and service7 records
1CAL (Cell Assisted Lipotransfer) Tissue Augmentation
CategoryRegenerative medicine treatment
Description

Regenerative medicine treatment in which the patient's own fat is combined with adipose-derived stem cells before injection, improving the survival rate of injected fat. Co-developed by Biomaster and the University of Tokyo Faculty of Medicine; provided at Cellport Clinic Yokohama.

2Cultured CAL
CategoryRegenerative medicine treatment
Description

Regenerative medicine treatment that adds cultured adipose-derived stem cells to the patient's fat for injection, for breast reconstruction and related applications. Clinical trials conducted from 2015 with treatment provided since 2020.

3PortStem (cultured adipose-derived stem cell product)
CategoryStem cell product
Description

Trademarked brand of cultivated adipose-derived stem cells developed by Biomaster, first clinically used at Cellport Clinic Yokohama.

4Cell Processing Contract Business
CategoryCell processing service
Description

Third-party cell processing service for medical institutions: clients send collected adipose tissue, and Biomaster isolates, cultures, and proliferates adipose-derived stem cells at its registered CPC using Kaneka-developed high-proliferation culture methods, then returns the cells.

5Cell Concentration Washing System
CategoryCell processing equipment
Description

Automated closed-circuit system that concentrates and washes cell suspensions and, with dedicated accessories, separates and extracts adipose-derived stem cells from adipose tissue; processes 50mL of adipose tissue to isolate SVF within 100 minutes. Developed and manufactured by Kaneka.

6Application Document Creation Support
CategoryRegulatory and technical support service
Description

Support service for medical institutions preparing to offer regenerative medicine, including application document preparation under the Act on the Safety of Regenerative Medicine, periodic report preparation, technical support, and physician/technician dispatch.

7Cellport Clinic Yokohama
CategoryRegenerative medicine clinic
Description

Clinic operated by Biomaster in Yokohama under the Structural Reform Special Zones Act, providing CAL and Cultured CAL breast reconstruction and related regenerative treatments directly to patients.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1株式会社カネカ (Kaneka Corporation)
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2011-01-01
Description

Since 2011, Biomaster has been part of the Kaneka Group. Kaneka provides high-proliferation culture methods for stem cell cultivation and manufactures the cell concentration washing system. Biomaster uses Kaneka's technology and equipment for its cell processing services and resells Kaneka's products to medical institutions.

biomaster.jp
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Nikon CeLL innovation Co., Ltd.
TypeDirect peer
Description

Subsidiary of Nikon providing cell processing and contract manufacturing services for regenerative medicine in Japan. Directly comparable to Biomaster as a domestic Japanese cell processing CDMO serving medical institutions under the regenerative medicine safety framework.

TypeRegional player
Description

China-based regenerative medicine company focused on umbilical cord mesenchymal stem cell therapies. Comparable as a stem cell therapy company with clinical application focus, and historical investor/affiliate in Biomaster's funding history.

TypeDirect peer
Description

Japanese cell therapy and regenerative medicine company providing cell processing services to medical institutions. Highly comparable to Biomaster's B2B cell processing contract model and use of approved regenerative medicine plans under Japan's Act on the Safety of Regenerative Medicine.

4Resonac Corporation (formerly Hitachi Chemical)
TypeDirect peer
Description

Japan-based CDMO with a dedicated regenerative medicine business providing cell processing, contract manufacturing, and CPC services to Japanese medical institutions. Closely comparable in service offering, regulatory positioning, and customer segment to Biomaster.

TypeBroad incumbent
Description

Major global CDMO with cell therapy and biologics manufacturing capabilities. Comparable as a contract developer/manufacturer serving regenerative medicine customers, albeit at a much larger scale and broader geographic scope than Biomaster.

TypeBroad incumbent
Description

Global biopharmaceutical CDMO with one of the largest cell and gene therapy manufacturing footprints. Comparable as a biologics/cell therapy CDMO, though much larger and more international than Biomaster's domestic-focused model.

TypeOthers
Description

Global supplier of bioprocessing equipment, single-use systems, and cell therapy manufacturing solutions. Comparable to Biomaster's Kaneka cell concentration washing system distribution and the broader bioprocess technology stack used in cell processing.

TypeRegional player
Description

Japan-based biopharmaceutical company with established cell therapy and regenerative medicine franchises, including TEMCELL for GvHD. Comparable as a domestic Japanese developer of cell-based therapies with strong regulatory navigation and clinical experience.

TypeOthers
Description

Global provider of blood and cell processing technologies and devices, including cell collection, processing, and expansion systems. Comparable as an enabling technology vendor in the cell processing workflow that Biomaster and its customers depend on.

TypeDirect peer
Description

Cell and gene therapy-focused CDMO supplying GMP-grade cell culture reagents, cytokines, and contract manufacturing services. Directly comparable to Biomaster's cell processing contract services and CPC-based biologics manufacturing for regenerative medicine.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biomaster

Regenerative Medicine Servicesbiomaster.jp

Biomaster firmographics

Firmographics
Name
Biomaster
Legal name
株式会社バイオマスター (Biomaster, Inc.)
Website
https://biomaster.jp
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Biomaster industry classification

Industry
Product category
Regenerative Medicine Services
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAL
GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGAIAG
Cell Culture & Bioprocess Lab Equipment (Bioreactors, Single-Use Systems, Controllers)

Keywords

  • Regenerative medicine services
  • Cell processing services
  • Adipose stem cell therapy
  • Cell concentration systems
  • Breast reconstruction treatment

Where Biomaster is headquartered

Location

Headquarters

HQ city
Yokohama
HQ country
Japan
HQ region
Asia

Offices2 records

Markets served

Biomaster business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Cell Processing Contract Business (细胞加工受托事业): Medical institutions send collected adipose tissue, Biomaster separates and cultures adipose-derived stem cells at its registered Cell Processing Facility (CPC) and returns them. Revenue is generated through cell processing fees charged to medical institutions. The CPC is registered with the Ministry of Health, Labour and Welfare under the Act on the Safety of Regenerative Medicine.
  2. Cell Concentration Washing System Sales: Sale of the Kaneka-developed cell concentration washing system and disposable kits to medical institutions. Institutions use the system for in-house SVF separation and extraction.
  3. Clinic Services (Cellport Clinic Yokohama): Direct patient services through the company's own clinic, providing CAL and cultured CAL breast reconstruction and related treatments. Operated under the Structural Reform Special Zones Act.
  4. Application and Technical Support Services: Support services for medical institutions seeking to offer regenerative medicine, including preparation of application documents for the Regenerative Medicine Safety Act, technical guidance, and physician/technician dispatch as needed.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Biomaster product offering

Product offering

Core offering

Biomaster is a regenerative medicine research and development company that provides cell processing contract services, cell concentration washing systems, and regulatory/technical support to medical institutions in Japan. It also operates Cellport Clinic Yokohama, where it delivers proprietary CAL (Cell Assisted Lipotransfer), Cultured CAL, and Step-CAL breast reconstruction and regenerative treatments directly to patients using adipose-derived stem cells.

Product overview

Biomaster is a research and development company specializing in regenerative medicine, offering a portfolio of three integrated regenerative medicine solutions: (1) Cell Processing Contract Business for third-party medical institutions, (2) Cell Concentration Washing System (KaneKa) equipment sales, and (3) Application/Technical Support for regenerative medicine approvals. Additionally, Biomaster operates Cellport Clinic Yokohama, which directly provides CAL (Cell Assisted Lipotransfer) and Cultured CAL treatments to patients, including the branded stem cell product PortStem.

Differentiator

Problem solved

Functional benefit

Brands

  • CAL組織増大術 (CAL): Cell Assisted Lipotransfer - regenerative medicine technique combining patient fat with adipose-derived stem cells to improve fat graft survival rates
  • PortStem
  • セルポートクリニック横浜 (Cellport Clinic Yokohama)

Products and services

  • CAL (Cell Assisted Lipotransfer) Tissue Augmentation Regenerative medicine treatment in which the patient's own fat is combined with adipose-derived stem cells before injection, improving the survival rate of injected fat. Co-developed by Biomaster and the University of Tokyo Faculty of Medicine; provided at Cellport Clinic Yokohama.
  • Cultured CAL Regenerative medicine treatment that adds cultured adipose-derived stem cells to the patient's fat for injection, for breast reconstruction and related applications. Clinical trials conducted from 2015 with treatment provided since 2020.
  • PortStem (cultured adipose-derived stem cell product) Trademarked brand of cultivated adipose-derived stem cells developed by Biomaster, first clinically used at Cellport Clinic Yokohama.
  • Cell Processing Contract Business Third-party cell processing service for medical institutions: clients send collected adipose tissue, and Biomaster isolates, cultures, and proliferates adipose-derived stem cells at its registered CPC using Kaneka-developed high-proliferation culture methods, then returns the cells.
  • Cell Concentration Washing System Automated closed-circuit system that concentrates and washes cell suspensions and, with dedicated accessories, separates and extracts adipose-derived stem cells from adipose tissue; processes 50mL of adipose tissue to isolate SVF within 100 minutes. Developed and manufactured by Kaneka.
  • Application Document Creation Support Support service for medical institutions preparing to offer regenerative medicine, including application document preparation under the Act on the Safety of Regenerative Medicine, periodic report preparation, technical support, and physician/technician dispatch.
  • Cellport Clinic Yokohama Clinic operated by Biomaster in Yokohama under the Structural Reform Special Zones Act, providing CAL and Cultured CAL breast reconstruction and related regenerative treatments directly to patients.

Quantifiable outcome

  • 1,300+ CAL procedures performed (as of June 2021)
  • +2 more outcomes

Companies that use Biomaster

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Biomaster technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Biomaster partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • 株式会社カネカ (Kaneka Corporation)coreTechnology or Integration · 1 January 2011Since 2011, Biomaster has been part of the Kaneka Group. Kaneka provides high-proliferation culture methods for stem cell cultivation and manufactures the cell concentration washing system. Biomaster uses Kaneka's technology and equipment for its cell processing services and resells Kaneka's products to medical institutions.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Biomaster competitors and assessment

Company assessment

Direct peers

  • Nikon CeLL innovation Co., Ltd. Subsidiary of Nikon providing cell processing and contract manufacturing services for regenerative medicine in Japan. Directly comparable to Biomaster as a domestic Japanese cell processing CDMO serving medical institutions under the regenerative medicine safety framework.
  • MEDINET Co., Ltd. Japanese cell therapy and regenerative medicine company providing cell processing services to medical institutions. Highly comparable to Biomaster's B2B cell processing contract model and use of approved regenerative medicine plans under Japan's Act on the Safety of Regenerative Medicine.
  • Resonac Corporation (formerly Hitachi Chemical): Japan-based CDMO with a dedicated regenerative medicine business providing cell processing, contract manufacturing, and CPC services to Japanese medical institutions. Closely comparable in service offering, regulatory positioning, and customer segment to Biomaster.
  • CellGenix GmbH: Cell and gene therapy-focused CDMO supplying GMP-grade cell culture reagents, cytokines, and contract manufacturing services. Directly comparable to Biomaster's cell processing contract services and CPC-based biologics manufacturing for regenerative medicine.

Regional players

  • Beike Biotechnology: China-based regenerative medicine company focused on umbilical cord mesenchymal stem cell therapies. Comparable as a stem cell therapy company with clinical application focus, and historical investor/affiliate in Biomaster's funding history.
  • JCR Pharmaceuticals Co., Ltd. Japan-based biopharmaceutical company with established cell therapy and regenerative medicine franchises, including TEMCELL for GvHD. Comparable as a domestic Japanese developer of cell-based therapies with strong regulatory navigation and clinical experience.

Broad incumbents

  • Catalent, Inc. Major global CDMO with cell therapy and biologics manufacturing capabilities. Comparable as a contract developer/manufacturer serving regenerative medicine customers, albeit at a much larger scale and broader geographic scope than Biomaster.
  • Lonza Group AG: Global biopharmaceutical CDMO with one of the largest cell and gene therapy manufacturing footprints. Comparable as a biologics/cell therapy CDMO, though much larger and more international than Biomaster's domestic-focused model.

Others

  • Cytiva (Danaher): Global supplier of bioprocessing equipment, single-use systems, and cell therapy manufacturing solutions. Comparable to Biomaster's Kaneka cell concentration washing system distribution and the broader bioprocess technology stack used in cell processing.
  • Terumo BCT: Global provider of blood and cell processing technologies and devices, including cell collection, processing, and expansion systems. Comparable as an enabling technology vendor in the cell processing workflow that Biomaster and its customers depend on.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Biomaster compliance and trust

Trust signal

Compliance3 records

Biomaster financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biomaster leadership team

Management profile

Number of profiles

Profiles1 record

Biomaster subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Biomaster funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biomaster M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biomaster

What does Biomaster do?

Biomaster is a regenerative medicine research and development company that provides cell processing contract services, cell concentration washing systems, and regulatory/technical support to medical institutions in Japan. It also operates Cellport Clinic Yokohama, where it delivers proprietary CAL (Cell Assisted Lipotransfer), Cultured CAL, and Step-CAL breast reconstruction and regenerative treatments directly to patients using adipose-derived stem cells.

Is Biomaster a public or private company?

Biomaster is a private company. It is classified as corporate owned and is currently operating.

When was Biomaster founded?

Biomaster was founded in 2002. It employs 11 to 50 people.

Where is Biomaster based?

Biomaster is headquartered in Yokohama, Japan, in the Asia region.

How does Biomaster make money?

Four revenue lines are on record. Cell Processing Contract Business (细胞加工受托事业) is the primary driver. The others are cell Concentration Washing System Sales, clinic Services (Cellport Clinic Yokohama) and application and Technical Support Services.

Who are Biomaster's main competitors?

Direct peers on record are Nikon CeLL innovation Co., Ltd., MEDINET Co., Ltd., Resonac Corporation (formerly Hitachi Chemical) and CellGenix GmbH. Regional players are Beike Biotechnology and JCR Pharmaceuticals Co., Ltd.. Broad incumbents are Catalent, Inc. and Lonza Group AG. Others are Cytiva (Danaher) and Terumo BCT.

Does Biomaster have an API?

No public API is recorded for Biomaster.

What industry is Biomaster in?

Biomaster's product category is Regenerative Medicine Services. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGAGAL, GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals